Matching articles for "Exubera"
An Inhaled Insulin (Afrezza)
The Medical Letter on Drugs and Therapeutics • March 2, 2015; (Issue 1463)
The FDA has approved an inhaled, rapid-acting, dry-powder
formulation of recombinant human insulin
(Afrezza – Mannkind/Sanofi) for treatment of adults
with type 1 or type 2 diabetes. In patients with type...
The FDA has approved an inhaled, rapid-acting, dry-powder
formulation of recombinant human insulin
(Afrezza – Mannkind/Sanofi) for treatment of adults
with type 1 or type 2 diabetes. In patients with type 1
diabetes, the drug must be used in combination with
long-acting insulin. Another inhaled, rapid-acting
insulin (Exubera) was approved in 2006 for the same
indication, but was withdrawn from the market the
following year.